COSCIENS Biopharma Inc. (CSCIF)
| Market Cap | 5.52M -56.7% |
| Revenue (ttm) | 8.00M -10.3% |
| Net Income | 4.05M |
| EPS | 3.84 |
| Shares Out | n/a |
| PE Ratio | 1.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 771 |
| Open | 5.30 |
| Previous Close | 4.92 |
| Day's Range | 5.30 - 5.30 |
| 52-Week Range | 2.37 - 11.55 |
| Beta | 1.90 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important bi... [Read more]
Financial Performance
In 2025, COSCIENS Biopharma's revenue was $7.50 million, a decrease of -21.79% compared to the previous year's $9.59 million. Losses were -$10.36 million, -32.34% less than in 2024.
Financial StatementsNews
COSCIENS Biopharma Inc. Completes Share Capital Amendment
TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), today announced the previously announced consolidation (the “Conso...
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company'...
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
TORONTO, ONTARIO, June 18, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the results from its annual general and special meeting o...
COSCIENS Biopharma Transcript: AGM 2026
The meeting covered board elections, auditor appointment, and approval of a share consolidation and split. Management addressed a shareholder question on strategic focus, confirming ongoing cost management and prioritization of PGX. All motions were approved.
COSCIENS Biopharma Inc. Reports Q1 2026 Results
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the first qua...
COSCIENS Biopharma Earnings release: Q1 2026
COSCIENS Biopharma released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
TORONTO, ONTARIO, April 20, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced today that it has filed a Rule 13e-3 Transaction Stateme...
COSCIENS Comments on Unusual Market Activity
TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is issuing this news release in response to unusual market activit...
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, pla...
COSCIENS Biopharma Earnings release: Q4 2025
COSCIENS Biopharma released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
COSCIENS Biopharma Annual report: Q4 2025
COSCIENS Biopharma has published its Q4 2025 annual report on March 25, 2026.
COSCIENS Provides Strategic Update
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”) today announced that the Company has made a strategic decision to ...
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagn...
COSCIENS Biopharma Inc. Announces Leadership Change
TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmace...
COSCIENS Biopharma Earnings release: Q3 2025
COSCIENS Biopharma released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq , while retaining the Company's listing on the TSX
COSCIENS Biopharma Earnings release: Q2 2025
COSCIENS Biopharma released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversifie...
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversifie...
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; C...
COSCIENS Biopharma Earnings release: Q1 2025
COSCIENS Biopharma released its Q1 2025 earnings on May 13, 2025, summarizing the period's financial results.
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operat...
COSCIENS Biopharma Annual report: Q4 2024
COSCIENS Biopharma has published its Q4 2024 annual report on April 9, 2025.
COSCIENS Biopharma Earnings release: Q4 2024
COSCIENS Biopharma released its Q4 2024 earnings on April 9, 2025, summarizing the period's financial results.
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a divers...